Provides the 2011 ACCF/AHA clinical practice guidelines for the diagnosis and management of hypertrophic cardiomyopathy.
Informs evidence-based hypertrophic cardiomyopathy management now; extends prior data synthesis into standardized recommendations for practice and research.
It is essential that the medical profession play a central role in critically evaluating the evidence related to drugs, devices, and procedures for the detection, management, or prevention of disease. Properly applied, rigorous, expert analysis of the available data documenting absolute and relative benefits and risks of these therapies and procedures can improve the effectiveness of care, optimize patient outcomes, and favorably fnect the cost of care by focusing resources on the most effective strategies.
No takes yet. Share an insight, caveat, or question.
Gersh et al. (2011) conducted a review in Hypertrophic cardiomyopathy. The 2011 ACCF/AHA guideline provides expert analysis of available data to optimize care and outcomes for patients with hypertrophic cardiomyopathy.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: